These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30953752)

  • 1. Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species.
    Wood FL; Shepherd S; Hayes A; Liu M; Grira K; Mok Y; Atrash B; Faisal A; Bavetsias V; Linardopoulos S; Blagg J; Raynaud FI
    Eur J Pharm Sci; 2019 Nov; 139():104899. PubMed ID: 30953752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
    Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.
    Moore AS; Faisal A; Mak GWY; Miraki-Moud F; Bavetsias V; Valenti M; Box G; Hallsworth A; de Haven Brandon A; Xavier CPR; Stronge R; Pearson ADJ; Blagg J; Raynaud FI; Chopra R; Eccles SA; Taussig DC; Linardopoulos S
    Blood Adv; 2020 Apr; 4(7):1478-1491. PubMed ID: 32282883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.
    Pasha MK; Jayaraman R; Reddy VP; Yeo P; Goh E; Williams A; Goh KC; Kantharaj E
    Drug Metab Lett; 2012 Mar; 6(1):33-42. PubMed ID: 22372550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
    Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
    Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology.
    Schulz-Utermoehl T; Spear M; Pollard CR; Pattison C; Rollison H; Sarda S; Ward M; Bushby N; Jordan A; Harrison M
    Drug Metab Dispos; 2010 Oct; 38(10):1688-97. PubMed ID: 20634336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
    Obermeier M; Yao M; Khanna A; Koplowitz B; Zhu M; Li W; Komoroski B; Kasichayanula S; Discenza L; Washburn W; Meng W; Ellsworth BA; Whaley JM; Humphreys WG
    Drug Metab Dispos; 2010 Mar; 38(3):405-14. PubMed ID: 19996149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro metabolism of BIIB021, an inhibitor of heat shock protein 90, in liver microsomes and hepatocytes of rats, dogs, and humans and recombinant human cytochrome P450 isoforms.
    Xu L; Woodward C; Khan S; Prakash C
    Drug Metab Dispos; 2012 Apr; 40(4):680-93. PubMed ID: 22217465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a cocktail of probe substrates for drug-metabolizing enzymes for the assessment of the metabolic capacity of hepatocyte preparations.
    Floby E; Briem S; Terelius Y; Sohlenius-Sternbeck AK
    Xenobiotica; 2004; 34(11-12):949-59. PubMed ID: 15801540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.
    Bavetsias V; Crumpler S; Sun C; Avery S; Atrash B; Faisal A; Moore AS; Kosmopoulou M; Brown N; Sheldrake PW; Bush K; Henley A; Box G; Valenti M; de Haven Brandon A; Raynaud FI; Workman P; Eccles SA; Bayliss R; Linardopoulos S; Blagg J
    J Med Chem; 2012 Oct; 55(20):8721-34. PubMed ID: 23043539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
    Ma XC; Ning J; Ge GB; Liang SC; Wang XL; Zhang BJ; Huang SS; Li JK; Yang L
    Drug Metab Dispos; 2011 Apr; 39(4):675-82. PubMed ID: 21205911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interspecies variation in phase I metabolism of bufalin in hepatic microsomes from mouse, rat, dog, minipig, monkey, and human.
    Ning J; Hou J; Wang P; Wu JJ; Dai ZR; Zou LW; Li W; Ge GB; Ma XC; Yang L
    Xenobiotica; 2015; 45(11):954-60. PubMed ID: 26053559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Prediction of Human Hepatic Clearance for P450 and Non-P450 Substrates from In Vivo Monkey Pharmacokinetics Study and In Vitro Metabolic Stability Tests Using Hepatocytes.
    Nishimuta H; Watanabe T; Bando K
    AAPS J; 2019 Jan; 21(2):20. PubMed ID: 30673906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs.
    Nishimuta H; Houston JB; Galetin A
    Drug Metab Dispos; 2014 Sep; 42(9):1522-31. PubMed ID: 24994071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic metabolism of MK-0457, a potent aurora kinase inhibitor: interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase.
    Ballard JE; Prueksaritanont T; Tang C
    Drug Metab Dispos; 2007 Sep; 35(9):1447-51. PubMed ID: 17537870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-specific binding of compounds in
    Gardner I; Xu M; Han C; Wang Y; Jiao X; Jamei M; Khalidi H; Kilford P; Neuhoff S; Southall R; Turner DB; Musther H; Jones B; Taylor S
    Xenobiotica; 2022 Aug; 52(8):943-956. PubMed ID: 36222269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Metabolism by Aldehyde Oxidase Leads to Poor Pharmacokinetic Profile in Rats for c-Met Inhibitor MET401.
    Zhang JW; Deng HB; Zhang CY; Dai JQ; Li Q; Zheng QG; Wan HX; Yu HP; He F; Xu YC; Zhao S; Zhang JYJ
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):669-680. PubMed ID: 31030415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
    Valles B; Schiller CD; Coassolo P; De Sousa G; Wyss R; Jaeck D; Viger-Chougnet A; Rahmani R
    Drug Metab Dispos; 1995 Oct; 23(10):1051-7. PubMed ID: 8654192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of aildenafil in vivo in rats and in vitro in mouse, rat, dog, and human liver microsomes.
    Li Y; Wu L; Gu Y; Si D; Liu C
    Drug Test Anal; 2014 Jun; 6(6):552-62. PubMed ID: 24311535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.